Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab

BACKGROUND Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improvement in outcome. To the authors' knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data suggest that subsets of patients with APCA may benefit from treatment with bevacizumab. The authors evaluated baseline serum albumin (b‐alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine‐based therapy with or without bevacizumab. METHODS Data were collected from individual databases from 7 prospective clinical trials. Patients were grouped by exposure to bevacizumab and by b‐alb level (≥ 3.4 g/L or